GlassScriptPhysician profile
Jacqueline Williams
NPI 1477092856
$657.75
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.11 · 2022: $116 · 2023: $277 · 2024: $25.83 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $133.91 | 2022-2023 | Adzenys Xr-Odt |
| Abbvie INC. | $125.99 | 2023-2025 | |
| Axsome Therapeutics, INC. | $79.77 | 2025 | Auvelity |
| Genentech USA, INC. | $51.46 | 2021 | |
| Uswm, LLC | $43.26 | 2023 | Zimhi, Lucemyra |
| Janssen Biotech, INC. | $35.99 | 2025 | Darzalex, Tecvayli, Erleada |
| Neurocrine Biosciences, INC. | $33.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $33.20 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.85 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.83 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.56 | 2022 | |
| Boston Scientific Corporation | $16.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.